quarta-feira, 4 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Via News Knowledge File

Pfizer Inc.

organization80% conf.·synced Nov 4, 2026

Pharmaceutical company, collaboration partner on Padcev

60
sourced metrics
676
relationships
20
stated objectives
3
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
30.00USD
Nov 3, 2026reference only
Price 52 Week Low
23.67USD
Nov 3, 2026reference only
Price 52 Week High
30.67USD
Nov 3, 2026reference only
Stock Return Ytd
19.1%
Nov 3, 2026reference only
Market Cap
170990207670USD
Nov 3, 2026reference only
Shares Outstanding
5699673589.0shares
Jul 29, 2026reference only
Cash
976000000.0USD
Jun 28, 2026reference only
Eps
-0.04USD_per_share
Jun 28, 2026reference only
Revenue
15034000000.0USD
Jun 28, 2026reference only
Total Liabilities
115639000000.0USD
Jun 28, 2026reference only
Cost Of Revenue
4092000000.0USD
Jun 28, 2026reference only
Stockholders Equity
85190000000.0USD
Jun 28, 2026reference only
Net Income
-248000000.0USD
Jun 28, 2026reference only
Total Assets
201131000000.0USD
Jun 28, 2026reference only
Operating Cash Flow
2615000000.0USD
Mar 29, 2026reference only
Capex
436000000.0USD
Mar 29, 2026reference only

Stated objectives

Invest in U.S. manufacturing and research

source
target: 70 billion USD stated

Achieve leading position in oncology

source
target: Market leadership in oncology stated

Implement drug pricing changes for consumers

source
target: Lower consumer drug costs by 2026-01-01 00:00:00stated

Build U.S. manufacturing capacity for Metsera obesity products

source
target: U.S.-produced anti-obesity drugs stated

Full-year revenue forecast

source
target: 59.5-62.5 billion USD by 2026-12-31 00:00:00stated

Revenue CAGR 2025-2030

source
target: 6 by 2030-01-01 00:00:00stated

Obtain global regulatory approvals for PADCEV plus pembrolizumab in cisplatin-eligible MIBC based on EV-304 results

source
stated

Enhance global ADC access through acquisition of Seagen

source
stated

Obtain regulatory approval for HYMPAVZI for treatment of hemophilia A or B with inhibitors from FDA and EMA

source
stated

Complete BASIS KIDS study to evaluate safety and efficacy of HYMPAVZI in children up to <18 years with hemophilia A or B with or without inhibitors

source
stated

Relationship graph · 676 connections

Developed by
215
Competes with
79
acquired by
40
Covered by
36
regulates
34
Partnered with
28
Employs
26
Supplies to
21

Via News coverage

Analistas preveem saída da Verizon do Dow Jones e substituição pela Alphabet
January 26, 2026
O Fim dos 'Magníficos 7': O Que Se Segue para os Investidores em Tecnologia e Saúde
January 20, 2026
AbbVie Fecha Acordo para Reduzir Preços de Medicamentos e Aumentar Investimento em I&D nos EUA
January 13, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI Moves Into Devices, Security and Platforms: Physical AI Data, On-Device Compute and Agent Governance Drive a Late-October Product Wave
In late October 2026, vendors across hardware, enterprise software and security launched products built around AI moving out of the cloud and into devices, workflows and physical systems. Examples include NVIDIA RTX Spark laptops with Adobe, ASUS and Windows support for local and hybrid AI, and Harvest Praxis and Encord on embodied or physical AI. Enterprise software and security vendors (Salesforce–Braze, Fortinet, ServiceNow, Cisco, Intuit) are consolidating AI-driven customer data, adding inline AI security and agent governance, and embedding AI in financial and accounting workflows. The finance link is indirect: it rests on M&A, fintech-adjacent AI tooling and the capital flowing into physical AI. No regulatory driver appears in the facts.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,548 documentos-fonte arquivados
Consulte estes dados → isubstrate.com